Moore Capital Management’s United Therapeutics UTHR Stock Holding History

Moore Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-89,979	Closed	-$18.8M	–	645
2022 Q3	$18.8M	Buy	89,979 +15,890	+21%	+$3.55M	0.44%	40
2022 Q2	$17.5M	Buy	74,089 +401	+0.5%	+$81.5K	0.46%	38
2022 Q1	$13.2M	Buy	73,688 +4,859	+7%	+$926K	0.34%	53
2021 Q4	$14.9M	Sell	68,829 -49,486	-42%	-$9.71M	0.3%	67
2021 Q3	$21.8M	Buy	118,315 +29,623	+33%	+$5.83M	0.33%	65
2021 Q2	$15.9M	Buy	+88,692	New	+$16.9M	0.23%	95
2015 Q2	–	Sell	-6,000	Closed	-$1.03M	–	518
2015 Q1	$1.03M	Buy	+6,000	New	+$915K	0.02%	353

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Moore Capital Management's UTHR Position: Q4 2022 in Review

Moore Capital Management sold out of United Therapeutics (UTHR) in Q4 2022, closing a stake of 89,979 shares — an estimated $18.8M sold.

Moore Capital Management first reported a position in UTHR in Q1 2015 and held it in 7 quarters. The position peaked at $21.8M in Q3 2021. 511 funds tracked by Wall St. Rank hold UTHR as of Q4 2022.

Moore Capital Management reported no remaining United Therapeutics position as of Q4 2022 after selling out during the quarter.
Moore Capital Management sold 89,979 United Therapeutics shares in Q4 2022, an estimated $18.8M.
Moore Capital Management first reported a position in United Therapeutics in Q1 2015 and held it in 7 quarters.
Moore Capital Management's United Therapeutics position peaked at $21.8M in Q3 2021.
511 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2022.

Based on Moore Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.